BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 20881474)

  • 1. A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study.
    Cardenes HR; Moore AM; Johnson CS; Yu M; Helft P; Chiorean EG; Vinson J; Howard TJ; Stephens AW; Tai DF; Loehrer PJ
    Am J Clin Oncol; 2011 Oct; 34(5):460-5. PubMed ID: 20881474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
    Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC
    Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas.
    Ammori JB; Colletti LM; Zalupski MM; Eckhauser FE; Greenson JK; Dimick J; Lawrence TS; McGinn CJ
    J Gastrointest Surg; 2003; 7(6):766-72. PubMed ID: 13129554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian Phase II study.
    Demols A; Peeters M; Polus M; Honoré P; Boterberg T; Gay F; Closon MT; Van Houtte P; Closset J; Van Laethem JL
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1351-6. PubMed ID: 16029792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
    Van Laethem JL; Demols A; Gay F; Closon MT; Collette M; Polus M; Houbiers G; Gastelblum P; Gelin M; Houtte PV; Closset J
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):974-80. PubMed ID: 12829132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival.
    Ogawa K; Ito Y; Hirokawa N; Shibuya K; Kokubo M; Ogo E; Shibuya H; Saito T; Onishi H; Karasawa K; Nemoto K; Nishimura Y;
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):559-65. PubMed ID: 22019243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.
    Baschnagel A; Shah C; Margolis J; Nadeau L; Stein J; Jury R; Robertson JM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e331-5. PubMed ID: 22420967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of primary radiation therapy and concurrent chemotherapy for patients with locally advanced pancreatic cancer.
    Magnino A; Gatti M; Massucco P; Sperti E; Faggiuolo R; Regge D; Capussotti L; Gabriele P; Aglietta M
    Oncology; 2005; 68(4-6):493-9. PubMed ID: 16020980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.
    Mamon HJ; Niedzwiecki D; Hollis D; Tan BR; Mayer RJ; Tepper JE; Goldberg RM; Blackstock AW; Fuchs CS;
    Cancer; 2011 Jun; 117(12):2620-8. PubMed ID: 21656739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ; Feng Y; Cardenes H; Wagner L; Brell JM; Cella D; Flynn P; Ramanathan RK; Crane CH; Alberts SR; Benson AB
    J Clin Oncol; 2011 Nov; 29(31):4105-12. PubMed ID: 21969502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas.
    Pipas JM; Mitchell SE; Barth RJ; Vera-Gimon R; Rathmann J; Meyer LP; Wagman RS; Lewis LD; McDonnell C; Colacchio TA; Perez RP
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1317-22. PubMed ID: 11483344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study.
    Moureau-Zabotto L; Phélip JM; Afchain P; Mineur L; André T; Vendrely V; Lledo G; Dupuis O; Huguet F; Touboul E; Balosso J; Louvet C
    J Clin Oncol; 2008 Mar; 26(7):1080-5. PubMed ID: 18309942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
    Mahadevan D; Chalasani P; Rensvold D; Kurtin S; Pretzinger C; Jolivet J; Ramanathan RK; Von Hoff DD; Weiss GJ
    Am J Clin Oncol; 2013 Jun; 36(3):239-43. PubMed ID: 22441342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine-based concurrent chemoradiotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
    Wang BH; Cao WM; Yu J; Wang XL
    Asian Pac J Cancer Prev; 2012; 13(5):2129-32. PubMed ID: 22901181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer.
    Wang X; Ni Q; Jin M; Li Z; Wu Y; Zhao Y; Feng F
    Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):404-7. PubMed ID: 12408777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study.
    Brade A; Brierley J; Oza A; Gallinger S; Cummings B; Maclean M; Pond GR; Hedley D; Wong S; Townsley C; Brezden-Masley C; Moore M
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1027-36. PubMed ID: 17197132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
    Blackstock AW; Tepper JE; Niedwiecki D; Hollis DR; Mayer RJ; Tempero MA
    Int J Gastrointest Cancer; 2003; 34(2-3):107-16. PubMed ID: 15361643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer.
    Marti JL; Hochster HS; Hiotis SP; Donahue B; Ryan T; Newman E
    Ann Surg Oncol; 2008 Dec; 15(12):3521-31. PubMed ID: 18830756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety.
    Gurka MK; Collins SP; Slack R; Tse G; Charabaty A; Ley L; Berzcel L; Lei S; Suy S; Haddad N; Jha R; Johnson CD; Jackson P; Marshall JL; Pishvaian MJ
    Radiat Oncol; 2013 Mar; 8():44. PubMed ID: 23452509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
    Esnaola NF; Chaudhary UB; O'Brien P; Garrett-Mayer E; Camp ER; Thomas MB; Cole DJ; Montero AJ; Hoffman BJ; Romagnuolo J; Orwat KP; Marshall DT
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):837-44. PubMed ID: 24606850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.